StemCell Institute (JP:7096)
:7096
Want to see JP:7096 full AI Analyst Report?
Total Valuation
StemCell Institute has a market cap or net worth of ¥6.76B. The enterprise value is ¥4.22B.
Market Cap¥6.76B
Enterprise Value¥4.22B
Share Statistics
StemCell Institute has 10,246,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,246,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
StemCell Institute’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 3.33%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.33%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee28.69M
Profits Per Employee1.59M
Employee Count98
Asset Turnover0.35
Inventory Turnover20.35
Valuation Ratios
The current PE Ratio of StemCell Institute is 42.7. StemCell Institute’s PEG ratio is -0.84.
PE Ratio42.7
PS Ratio2.75
PB Ratio2.88
Price to Fair Value2.88
Price to FCF-23.04
Price to Operating Cash Flow0.00
PEG Ratio-0.84
Income Statement
In the last 12 months, StemCell Institute had revenue of 2.81B and earned 155.92M in profits. Earnings per share was 15.44.
Revenue2.81B
Gross Profit1.71B
Operating Income202.66M
Pretax Income217.79M
Net Income155.92M
EBITDA359.42M
Earnings Per Share (EPS)15.44
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
StemCell Institute pays an annual dividend of ¥25, resulting in a dividend yield of ―
Dividend Per Share¥25
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-35.92%
50-Day Moving Average720.60
200-Day Moving Average825.96
Relative Strength Index (RSI)42.34
Average Volume (3m)28.64K
Important Dates
StemCell Institute upcoming earnings date is Aug 12, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
StemCell Institute as a current ratio of 1.17, with Debt / Equity ratio of 17.67%
Current Ratio1.17
Quick Ratio1.16
Debt to Market Cap0.06
Net Debt to EBITDA-6.57
Interest Coverage Ratio37.20
Taxes
In the past 12 months, StemCell Institute has paid 86.78M in taxes.
Income Tax86.78M
Effective Tax Rate0.40
Enterprise Valuation
StemCell Institute EV to EBITDA ratio is 14.96, with an EV/FCF ratio of -16.01.
EV to Sales1.91
EV to EBITDA14.96
EV to Free Cash Flow-16.01
EV to Operating Cash Flow73.12
Balance Sheet
StemCell Institute has ¥2.71B in cash and marketable securities with ¥497.26M in debt, giving a net cash position of ¥2.21B billion.
Cash & Marketable Securities¥2.71B
Total Debt¥497.26M
Net Cash¥2.21B
Net Cash Per Share¥215.94
Tangible Book Value Per Share¥304.44
Margins
Gross margin is 60.90%, with operating margin of 7.21%, and net profit margin of 5.55%.
Gross Margin60.90%
Operating Margin7.21%
Pretax Margin7.75%
Net Profit Margin5.55%
EBITDA Margin12.78%
EBIT Margin7.21%
Analyst Forecast
The average price target for StemCell Institute is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast4.93%
EPS Growth Forecast-59.54%